Hair-Loss Drug Stocks Soar as Wall Street's Next Big Bet After GLP-1 Boom
4 Articles
4 Articles
Following obesity treatments, Wall Street is now focusing on hair loss treatments as a promising new market. Stock prices of related companies, such as Veradermics, Abcy, and Cosmo, are rising as they achieve results in new drug clinical trials. However, the high failure rate of new drug development and difficulties with insurance coverage remain variables hindering market expansion, requiring a cautious approach.
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
Drugmakers found a promising cure for the obesity epidemic and their stocks were rewarded for it. Now, investors are salivating over a new crop of companies tackling a more purely aesthetic problem: baldness. Pattern hair loss affects an estimated 50 million men and 30 million women in the US, but there have been no new approved drugs since the late 1990s. The promise of novel treatments has sent shares of Veradermics Inc., which trades as “MANE…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
